Rituximab induced lung injury
Abstract Background Rituximab is a chimeric human-mouse immunoglobulin monoclonal antibody with high affinity for CD20 surface antigens expressed by pre-B and B cells that is commonly used as the mainstay for the treatment of B cell non-Hodgkin’s lymphomas, including diffuse large B-cell lymphoma (D...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMC
2025-07-01
|
| Sarja: | BMC Pulmonary Medicine |
| Aiheet: | |
| Linkit: | https://doi.org/10.1186/s12890-025-03802-x |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|